X
[{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ichnos Sciences Presents Positive Data from Ongoing Phase 2b Study of Telazorlimab in Atopic Dermatitis At The 2021 SID Virtual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$23.6 million","newsHeadline":"Ichnos Sciences and Almirall Enter Into a Licensing Agreement for First-In-Class Il-1 RAP Antagonist Monoclonal Antibody","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ichnos Sciences Announces Selection Of Trispecific Antibody Isb 2001 As Next Clinical Candidate For Relapsed\/Refractory Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ichnos Sciences Announces Initiation Of First-In-Human Study For ISB 1442","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Bispecific (CD38 x CD47) antibody Innate Cell Modulator, ISB 1442","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ichnos Sciences Receives Orphan Drug Designation for First-in-class Trispecific Antibody, ISB 2001","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Astria Therapeutics","pharmaFlowCategory":"D","amount":"$320.0 million","upfrontCash":"$15.0 million","newsHeadline":"Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Ichnos Sciences","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ichnos and Glenmark Take a Collaborative Leap to Accelerate Innovation in Cancer Treatment with their alliance -'Ichnos Glenmark Innovation'","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Ichnos Sciences
Filters
Companies By Therapeutic Area
Details:
The collaboration aims to accelerate new drug discovery in cancer treatment combining Ichnos' research and development proficiencies in novel biologics with those of Glenmark in new small molecules, including GRC 54276, to treat hematological malignancies and solid tumors.
Lead Product(s):
GRC 54276,Pembrolizumab
Therapeutic Area: Oncology
Product Name: GRC 54276
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Glenmark Pharmaceuticals
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
January 30, 2024
Details:
Under the terms of the license agreement, Astria plans to develop the lead candidate, called STAR-0310, a monoclonal antibody OX40 antagonist that incorporates YTE half-life extension technology, for the treatment of AD.
Lead Product(s):
STAR-0310
Therapeutic Area: Dermatology
Product Name: STAR-0310
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Astria Therapeutics
Deal Size: $320.0 million
Upfront Cash: $15.0 million
Deal Type: Licensing Agreement
October 11, 2023
Details:
ISB 2001, Ichnos' third clinical-stage asset to receive ODD for the treatment of multiple myeloma, is the company's first BCMA x CD38 x CD3 TREAT™ trispecific antibody based on the company's proprietary BEAT® platform, which enables the development of immune cell engagers.
Lead Product(s):
ISB 2001
Therapeutic Area: Oncology
Product Name: ISB 2001
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 07, 2023
Details:
ISB 1442 is a biparatopic 2+1 BEAT® bispecific antibody targeting CD38 and CD47, for the treatment of acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL).
Lead Product(s):
ISB 1442
Therapeutic Area: Oncology
Product Name: ISB 1442
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 21, 2023
Details:
ISB 1442 is a biparatopic bispecific antibody that combines two proprietary anti-CD38 binding arms, each targeting different regions on CD38, with an antagonistic anti-CD47 arm, making it equivalent to a trispecific antibody.
Lead Product(s):
ISB 1442
Therapeutic Area: Oncology
Product Name: ISB 1442
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 28, 2022
Details:
In vitro studies showed that ISB 2001 exhibited increased killing potency of tumor cells compared to all tested antibodies that are either currently approved therapeutics for multiple myeloma or being tested in ongoing clinical studies.
Lead Product(s):
ISB 2001
Therapeutic Area: Oncology
Product Name: ISB 2001
Highest Development Status: IND Enabling
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 09, 2022
Details:
Under the agreement, Almirall is granted global rights to develop and commercialize ISB 880, monoclonal antibody for autoimmune diseases. Ichnos will retain rights for antibodies acting on the IL-1RAP pathway for oncology indications.
Lead Product(s):
ISB 880
Therapeutic Area: Immunology
Product Name: ISB 880
Highest Development Status: IND Enabling
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Almirall
Deal Size: Undisclosed
Upfront Cash: $23.6 million
Deal Type: Licensing Agreement
December 14, 2021
Details:
The two highest doses of telazorlimab, 300 mg and 600 mg administered every two weeks, were statistically superior to placebo. Telazorlimab was well-tolerated during the study to date.
Lead Product(s):
Telazorlimab
Therapeutic Area: Dermatology
Product Name: ISB 830
Highest Development Status: Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Glenmark Pharmaceuticals
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 03, 2021